- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00062907
Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer
December 5, 2006 updated by: Corixa Corporation
Phase I Open-Label Dose Escalation Trial Evaluating The Safety And Immunogenicity Of Sequential Administration Of Recombinant DNA And Adenovirus Expressing L523S Protein In Patients With Early Stage Non-Small Cell Lung Cancer
The purpose of this trial is to examine the safety and immunogenicity of a therapeutic vaccine regimen with recombinant DNA and adenovirus expressing L523S protein in patients with early stage non-small cell lung cancer.
The vaccine regimen will consist of two fixed doses of recombinant DNA (pVAX/L523S) followed by two doses of recombinant adenovirus (Ad/L523S).
The trial will evaluate the dose escalation of Ad/L523S through three cohorts of patients.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The primary objective of the study is to evaluate the safety of the vaccine regimen administered as two doses of pVAX/L523S and two doses of Ad/L523S.
The secondary objectives of the study are:
- To provide initial evidence as to whether CD8+ and CD4+ T cell responses specific for L523S protein can be elicited by two doses of pVAX/L523S followed by two doses of Ad/L523S
- To provide initial evidence as to whether antibody responses specific for L523S protein can be elicited by two doses of pVAX/L523S followed by two doses of Ad/L523S
- To investigate the extent to which dose escalation of Ad/L523S affects the elicited immune response
Study Type
Interventional
Enrollment
9
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Ocoee, Florida, United States, 34761
- Recruiting
- Cancer Centers of Florida
-
Contact:
- Bobbi Rehm, RN
- Phone Number: 407-292-3042
- Email: brehm@usoncology.com
-
Principal Investigator:
- Barry S. Berman, MD
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Mary Crowley Medical Research Clinic
-
Principal Investigator:
- John Nemunaitis, MD
-
Contact:
- Jennifer Edwards
- Phone Number: 214-658-1944
- Email: jedwards@mcmrc.com
-
Tyler, Texas, United States, 75702
- Recruiting
- Tyler Cancer Center
-
Principal Investigator:
- Donald Richards, MD
-
Contact:
- Linda Dunklin, RN
- Phone Number: 903-579-9800
- Email: linda.dunklin@usoncology.com
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Swedish Cancer Institute
-
Contact:
- Jane Arthur, RN
- Phone Number: 206-386-6921
- Email: jane.arthur@swedish.org
-
Principal Investigator:
- Howard West, MD
-
Spokane, Washington, United States, 99218
- Recruiting
- Cancer Care Northwest
-
Contact:
- Rose Miller, RN, OCN
- Phone Number: 509-228-1432
- Email: rosalee.miller@usoncology.com
-
Principal Investigator:
- Stephen Anthony, D.O.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
INCLUSION CRITERIA:
- Histologically and surgical confirmed diagnosis and stage of IB, IIA, or IIB non-small cell lung cancer (NSCLC) according to the Revised International System for Staging Lung Cancer
- Primary surgical resection of lung cancer greater than or equal to 4 weeks and less than or equal to 3 years prior to the Day 0 visit
- No evidence of disease by standard diagnostic tests
- Chest X-ray and physical examination showing no active disease
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- WBC count greater than or equal to 3,000 cells/mm3 and ANC greater than or equal to 1,500 cells/mm3
- Hemoglobin value greater than or equal to 10.0 g/dL and a platelet count greater than or equal to 125,000 cells/mm3
- Adequate renal function (defined as serum creatinine <1.5 times the upper limit of normal for females and males)
- Normal hepatic function (defined as serum bilirubin <1.5 times the upper limit of normal, AST <2.5 times the upper limit of normal and alkaline phosphatase <1.5 times the upper limit of normal)
- Ability to understand and willingness to sign an IRB-approved written consent prior to study enrollment
- Female patients must be greater than or equal to 60 years of age, or greater than or equal to 5 years amenorrhea or surgically sterile
- Male patients who are capable of fathering a child and whose partners are capable of having a child must agree to use adequate contraception for 6 months after enrollment (for men or women-surgical sterilization; for women-hormonal contraceptives, vaginal ring or IUD)
- Absolute CD4+ cell count of >200 cells/mm3
EXCLUSION CRITERIA:
- Received pre- or post-operative radiotherapy
- Received prior biologic, immunologic, or gene therapy for cancer
- Received an investigational drug (new chemical entity) within three months of study entry
- Received antibiotics within 2 weeks of Day 0 visit
- Received systemic or inhaled corticosteroids or immunosuppressive therapy within 4 weeks of Day 0 visit (Use of topical corticosteroids and/or eye drops containing glucocorticosteroids is acceptable)
- History of active autoimmune diseases such as, but not limited to, systemic lupus erythematosis, sarcoidosis, rheumatoid arthritis, glomerulonephritis, vasculitis, or inflammatory bowel disease
- History of bleeding in stools and/or diarrhea within 4 weeks of Day 0 visit
- History of anaphylaxis or severe allergic reaction to vaccines or unknown allergens
- Received any commercial vaccine within 2 weeks of Day 0 visit
- Received a major organ allograft
- Current or previous diagnosis of paraneoplastic syndrome
- Evidence of a clinically significant active pulmonary infection, emphysema, FeV1 less than or equal to 50% predicted, DLCO less than or equal to 50% predicted, pulse oximetry less than or equal to 92% at the time of study entry
- Known to be HIV positive
- Results of virology screening indicate positive serology for HCV (hepatitis C virus) and/or HBsAG (hepatitis B surface antigen). Positive serology for HBV antibodies is allowed.
- History of other malignancies at other sites, except effectively treated non-melanoma skin cancers, superficial bladder cancer or carcinoma in situ of the cervix or an effectively treated malignancy that has been in remission for greater than 5 years and is highly likely to have been cured
- Uncontrolled medical problems (neurological, cardiovascular, gastrointestinal, genitourinary or other illness) considered as unwarranted high risk for investigational new drug treatment
- Patient is lactating
- Staging classification of TX or NX or MX
- Prior adjuvant chemotherapy within 8 weeks prior to the Day 0 visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2003
Study Registration Dates
First Submitted
June 17, 2003
First Submitted That Met QC Criteria
June 18, 2003
First Posted (Estimate)
June 19, 2003
Study Record Updates
Last Update Posted (Estimate)
December 6, 2006
Last Update Submitted That Met QC Criteria
December 5, 2006
Last Verified
November 1, 2004
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCL5001-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)WithdrawnStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Recombinant DNA- pVAX/L523S
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsAustralia
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
Shandong Province Centers for Disease Control and...Centers for Disease Control and Prevention, China; National Institutes for...Completed
-
Benha UniversityNew Jeddah Clinic HospitalCompletedHepatitis B | Hemodialysis Complication
-
National Institute of Allergy and Infectious Diseases...HIV Vaccine Trials NetworkTerminated
-
Kirby InstituteThai Red Cross AIDS Research CentreTerminated
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCCompletedCervical Cancer | Precancerous Condition | Nonneoplastic ConditionIndia
-
Worcester HIV VaccineBrigham and Women's Hospital; Access to Advanced Health Institute (AAHI)CompletedHIV InfectionsUnited States